Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lumisight

(Pegulicianine)

Small molecule

LLumicell, Inc.

0

Indications

1

Total Trials

1

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

6

Patents

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Fluorescence

NCT06957821

Clinical

Trials by Indication[1]

Fluorescence1 trial

Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques

Not yet recruiting·MMassachusetts General Hospital·Phase 1·NCT06957821·25 enrolled

Regulatory

FDA Approval Timeline[3]

Apr 17, 2024

LUMISIGHT

NDA NDA214511

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pegulicianine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pegulicianine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA214511). U.S. Food & Drug Administration.
[4]
FDA Orange Book — Patent and exclusivity data for Lumisight. U.S. Food & Drug Administration.
[5]
SEC EDGAR — Lumicell, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: LLumicell, Inc.

Patent Landscape[4]

Patent Cliff

Sep 1, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11592396Sep 1, 2030

9155471Oct 12, 2031

10285759Dec 8, 2031

9532835Dec 8, 2031

9032965Dec 8, 2031

1 more patents

9763577Sep 14, 2034

Related News